HNSBF
Price
$2.74
Change
-$0.26 (-8.67%)
Updated
Jul 17 closing price
Capitalization
268.94M
ISCO
Price
$0.14
Change
+$0.01 (+7.69%)
Updated
Sep 3 closing price
Capitalization
1.12M
Interact to see
Advertisement

HNSBF vs ISCO

Header iconHNSBF vs ISCO Comparison
Open Charts HNSBF vs ISCOBanner chart's image
Hansa Medical AB
Price$2.74
Change-$0.26 (-8.67%)
Volume$7.12K
Capitalization268.94M
International Stem Cell
Price$0.14
Change+$0.01 (+7.69%)
Volume$7.11K
Capitalization1.12M
HNSBF vs ISCO Comparison Chart in %
Loading...
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HNSBF vs. ISCO commentary
Sep 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HNSBF is a Hold and ISCO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2025
Stock price -- (HNSBF: $2.74 vs. ISCO: $0.14)
Brand notoriety: HNSBF and ISCO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HNSBF: 120% vs. ISCO: 97%
Market capitalization -- HNSBF: $268.94M vs. ISCO: $1.12M
HNSBF [@Biotechnology] is valued at $268.94M. ISCO’s [@Biotechnology] market capitalization is $1.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HNSBF’s FA Score shows that 0 FA rating(s) are green whileISCO’s FA Score has 1 green FA rating(s).

  • HNSBF’s FA Score: 0 green, 5 red.
  • ISCO’s FA Score: 1 green, 4 red.
According to our system of comparison, ISCO is a better buy in the long-term than HNSBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HNSBF’s TA Score shows that 1 TA indicator(s) are bullish while ISCO’s TA Score has 1 bullish TA indicator(s).

  • HNSBF’s TA Score: 1 bullish, 1 bearish.
  • ISCO’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, HNSBF is a better buy in the short-term than ISCO.

Price Growth

HNSBF (@Biotechnology) experienced а 0.00% price change this week, while ISCO (@Biotechnology) price change was +6.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was +11.73%, and the average quarterly price growth was +36.34%.

Industries' Descriptions

@Biotechnology (+2.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HNSBF($269M) has a higher market cap than ISCO($1.12M). ISCO YTD gains are higher at: 72.202 vs. HNSBF (-8.667). ISCO has higher annual earnings (EBITDA): 128K vs. HNSBF (-506.53M). HNSBF has more cash in the bank: 354M vs. ISCO (920K). ISCO has less debt than HNSBF: ISCO (3.85M) vs HNSBF (906M). HNSBF has higher revenues than ISCO: HNSBF (196M) vs ISCO (9.2M).
HNSBFISCOHNSBF / ISCO
Capitalization269M1.12M23,996%
EBITDA-506.53M128K-395,730%
Gain YTD-8.66772.202-12%
P/E RatioN/AN/A-
Revenue196M9.2M2,130%
Total Cash354M920K38,478%
Total Debt906M3.85M23,563%
FUNDAMENTALS RATINGS
HNSBF vs ISCO: Fundamental Ratings
HNSBF
ISCO
OUTLOOK RATING
1..100
4714
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7640
P/E GROWTH RATING
1..100
10088
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is somewhat better than the same rating for HNSBF (67). This means that ISCO’s stock grew somewhat faster than HNSBF’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as HNSBF (100). This means that ISCO’s stock grew similarly to HNSBF’s over the last 12 months.

ISCO's SMR Rating (100) in the null industry is in the same range as HNSBF (100). This means that ISCO’s stock grew similarly to HNSBF’s over the last 12 months.

ISCO's Price Growth Rating (40) in the null industry is somewhat better than the same rating for HNSBF (76). This means that ISCO’s stock grew somewhat faster than HNSBF’s over the last 12 months.

ISCO's P/E Growth Rating (88) in the null industry is in the same range as HNSBF (100). This means that ISCO’s stock grew similarly to HNSBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HNSBFISCO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
8%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
11%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
7%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 28 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
13%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KFS14.400.37
+2.64%
Kingsway Financial Services
XCH1.20N/A
N/A
XCHG Ltd
QDEL28.47-0.21
-0.73%
QuidelOrtho Corp
KNSL451.85-3.55
-0.78%
Kinsale Capital Group
WLDS1.03-0.03
-3.27%
Wearable Devices Ltd

HNSBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with ENSC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HNSBF
1D Price
Change %
HNSBF100%
N/A
ENSC - HNSBF
33%
Loosely correlated
-1.64%
CVAC - HNSBF
33%
Poorly correlated
-0.74%
MLLCF - HNSBF
27%
Poorly correlated
N/A
GNPX - HNSBF
25%
Poorly correlated
-10.37%
GRI - HNSBF
25%
Poorly correlated
-6.02%
More

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and HNSBF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and HNSBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
HNSBF - ISCO
22%
Poorly correlated
N/A
CRDF - ISCO
20%
Poorly correlated
+3.23%
LIXT - ISCO
7%
Poorly correlated
-5.36%
INTI - ISCO
7%
Poorly correlated
-1.25%
INRLF - ISCO
5%
Poorly correlated
N/A
More